Dr. Scarpato on NMIBC: “We need more biomarkers”
“In non–muscle-invasive bladder cancer, we need more biomarkers, something that can hopefully reduce the frequency of invasive procedures for these patients,” says Kristen Scarpato, MD, MPH.
In this video, Kristen Scarpato, MD, MPH, discusses what is being done to improve the treatment options for patients with non–muscle-invasive bladder cancer, including what she does in her own practice. These ideas were focused on in a case-based discussion on intermediate-risk non–muscle-invasive bladder cancer that took place during the 2021 Society of Urologic Oncology Annual Meeting. Scarpato is an associate professor, residency program director, and vice chair of education in the department of urology at the Vanderbilt University Medical Center in Nashville, Tennessee.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC
April 5th 2024“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
